MDMA use among young people in Spain is common in recreational settings, with 80.6% of survey respondents reporting past-year use. Although many users adopt self-care strategies, only 27.5% follow the recommended dosing interval, and use often involves combining MDMA with alcohol and cannabis. Information about risks is validated within peer networks, which shapes both risk perception and consumption patterns. The findings suggest that effective risk-reduction strategies should integrate scientific evidence with user experiences and be tailored to the social and consumption dynamics of young people.
LSD, psilocibina y ketamina muestran potencial terapéutico en el tratamiento y prevención de las cefaleas. El LSD es especialmente eficaz como profiláctico, la ketamina puede abortar ataques agudos, y la psilocibina es efectiva en ambos aspectos. La evidencia proviene principalmente de estudios en pacientes con migraña y cefalea en racimos, aunque existen limitaciones metodológicas que dificultan la generalización de los resultados. Se necesita más investigación en este campo emergente.